Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96I99

UPID:
SUCB2_HUMAN

ALTERNATIVE NAMES:
GTP-specific succinyl-CoA synthetase subunit beta; Succinyl-CoA synthetase beta-G chain

ALTERNATIVE UPACC:
Q96I99; C9JVT2; O95195; Q6NUH7; Q86VX8; Q8WUQ1

BACKGROUND:
GTP-specific succinyl-CoA synthetase subunit beta is integral to the TCA cycle, facilitating the only instance of substrate-level phosphorylation in this pathway. By hydrolyzing succinyl-CoA to produce GTP, it supports essential cellular functions. The enzyme's beta subunit is critical for binding the succinate substrate, highlighting its specificity and importance in metabolic processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of GTP-specific succinyl-CoA synthetase subunit beta could unveil novel therapeutic avenues. Its involvement in fundamental metabolic pathways underscores its potential as a therapeutic target, particularly in diseases related to energy metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.